Article

Clinical and immunological aspects of HIV infection in drug addicts

Clinic of Infectious Disease, Institute of Internal Medicine, Infectious Disease and Immunopathology, University of Milan, Milan 20157, Italy
Clinical Immunology and Immunopathology 02/1989; 50(1). DOI: 10.1016/0090-1229(89)90124-4

ABSTRACT Intravenous drug users (IVDUs) account for more than 64% of the total AIDS cases in Italy. The IVDUs' seropositivity rate is >70% in Milan and >50% in the main cities of Italy. The first evidence of seropositivity in this population dates back to 1979. In a cohort study performed in Milan the rate of progression to overt AIDS among IVDUs was 6% in 3 years (1984–1987). At presentation, more than 75% of the subjects had CD4+ cell counts higher than 400/mm3 (mean 631, median 528, mode 465). These values are significantly higher than those observed in the same population in New York, the only American city with HIV-infection spread comparable to that observed in Milan. The probability of having CD4+ cell counts lower than 400, 300, and 200/mm3 in relation to the length of follow-up was, respectively, 50, 40, and 2% after 36 months from presentation. At the same end point, subjects presenting less than 400 CD4+ cells at entry had 30% probability of falling under 200 cell/mm3. The pattern of CD4+ cells, as much as the low percentage of yearly progression to overt AIDS, is probably related to the recent, even if rapid, spread of infection among IVDUs in Italy. The clinical features of overt AIDS present some differences between IVDUs and other at-risk groups. Among U.S. IVDUs with AIDS, Kaposi's sarcoma is infrequent (2.9% vs 27.7% in homosexual men) while mycotic infections such as deep candidiasis and cryptococcosis are significantly more frequent. The same pattern has been observed in our case file in Milan: esophageal candidiasis represents the most frequent cause of diagnosis of overt AIDS. Mycotic infections, overall, are more frequent than in U.S. IVDUs. The increased rate of mycotic infections among IVDUs might be justified by altered functions of nonspecific immunity, such as PMNL killing and phagocytosis of Candida albicans spores, impaired in HIV-infected IVDUs, but generally normal in infected subjects belonging to the other at-risk groups.

0 Followers
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of functional properties of natural killer cells displayed in reactions of natural cytotoxicity and noncytotoxic regulatory intercellular interactions suggests that this population of lymphocytes is involved in endogenous biological retranslation. In the immune system, retranslation is the production of regulatory immunoactive cytokines by a cell, cellular complex, or functional complex. The substances produced are identical to those affecting these structures. Various forms of endogenous biological retranslation in humans and higher animals, as well as its phylogenetic and ontogenetic manifestations (on the basis of noncytotoxic regulatory interactions of natural killer cells with cells of lymphoid or nonlymphoid nature) during evolution of the complex of immunobiological surveillance are considered. The axiomatic basis of retranslation realized through the system of natural cytotoxicity was established. Prospects for application of the methodology of endogenous biological retranslation to experimental and clinical studies of functioning of natural killer cells are considered.
    Bulletin of Experimental Biology and Medicine 08/1998; 126(2):751-761. DOI:10.1007/BF02446901 · 0.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To study the trend in mortality from 1980 to 1991 in a cohort of 2432 intravenous drug users (IVDU) enrolled between 1 November 1980 and 31 December 1988. In addition, to evaluate the impact of HIV-1 infection on mortality. Design: The vital status of people enrolled in the cohort was ascertained at registry offices of the municipalities of residence. Cause of death was determined by reviewing death certificates, clinical records and autopsy reports. Within the cohort, the causes of death of HIV-1-infected subjects were compared with those of subjects of undetermined serologic status. Setting: Municipalities of the metropolitan area of Milan. Results: The cohort was followed-up for 16415 person-years (PY) and 413 deaths were observed up to 30 June 1991. Mortality was 25.2 per 1000 PY, 20.5 times greater than that of the general population of the same age and sex. The leading cause of death was drug overdose, followed by AIDS (death rates 9.2 and 8.8 per 1000 PY, respectively). Mortality remained under 16 per 1000 PY from 1981 to 1986, and then increased rapidly to 63.8 per 1000 PY in the first half of 1991. AIDS and overdose accounted for most of this increase, with AIDS becoming the leading cause of death from 1989. Mortality in HIV-1-infected IVDU was higher than in IVDU as a whole (48.0 versus 19.9 per 1000 PY), and the difference was entirely due to AIDS and infectious diseases. Conclusion: The overall mortality rate and the mortality for AIDS and overdose were markedly higher than in other European countries in the same risk group. HIV-1 infection does not appear to affect the mortality for causes other than AIDS and infectious diseases. (C) Lippincott-Raven Publishers.
    AIDS 09/1994; 8(10). DOI:10.1097/00002030-199410000-00013 · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In Reply. —Dr Winkelstein raises the possibility of selection bias in our analysis of CD4 lymphocyte decline in the ALIVE cohort of IVDUs. This bias must always be a serious concern in any longitudinal study; for this reason and because the decline in CD4 lymphocytes in our cohort of IVDUs was lower than that reported by others, we looked for evidence of significant bias in our original analysis, as Winkelstein notes. However, we did not find such evidence, and we concluded that while the possibility of selection bias could not be completely excluded, a large bias did not appear likely, for the reasons already stated. We have recently updated the analysis of CD4 lymphocyte changes in our cohort based on an additional year of follow-up. Eighteen-month follow-up data are now available for 537 (85.7%) of the 627 cohort members, and the median rate of CD4 lymphocyte change is -7.4/μL per
    JAMA The Journal of the American Medical Association 03/1992; 267(12):1631-1636. DOI:10.1001/jama.267.12.1631 · 30.39 Impact Factor